Nab-paclitaxel plus S-1 versus oxaliplatin plus S-1 as first-line treatment in advanced gastric cancer: results of a multicenter, randomized, phase III trial (GAPSO study)

BACKGROUND: This study aimed to investigate the superiority of nab-paclitaxel plus S-1 (AS) over oxaliplatin plus S-1 (SOX) in patients with advanced gastric cancer (AGC). METHODS: In this multicenter, randomized, phase III superiority trial, eligible patients with unresectable, locally advanced gas...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Yu-Hong, Yu, Xiong-Jie, Xu, Hui-Ting, Zhuang, Liang, Zhang, Ming-Sheng, Zou, Yan-Mei, Fu, Qiang, Qiu, Hong, Yuan, Xiang-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379568/
https://www.ncbi.nlm.nih.gov/pubmed/35983025
http://dx.doi.org/10.1177/17588359221118020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379568/
https://www.ncbi.nlm.nih.gov/pubmed/35983025
http://dx.doi.org/10.1177/17588359221118020

Ejemplares similares